| Type 2 Diabetes Mellitus |
1 |
1 |
| Medicare |
0 |
0.99 |
| SGLT2 Inhibitor |
0 |
0.47 |
| Hypertension |
0 |
0.3 |
| GLP-1 Receptor Agonist |
0 |
0.25 |
| Lipids Management |
0 |
0.25 |
| Revenue and Practice Management |
0 |
0.25 |
| Renal Disease |
0 |
0.23 |
| Social Determinants of Health |
0 |
0.21 |
| Receptors |
0 |
0.2 |
| Angiotensin II Receptor Blockade |
0 |
0.19 |
| Medicaid |
0 |
0.14 |
| Pedal |
0 |
0.14 |
| Cardiovascular Risk Management |
0 |
0.13 |
| Diabetic Foot |
0 |
0.13 |
| Patient Safety |
0 |
0.13 |
| Hemoglobin A1c |
0 |
0.1 |
| ACE Inhibitor |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Drug and Treatment Safety |
0 |
0.07 |
| Geriatrics |
0 |
0.07 |
| Health Equity |
0 |
0.07 |
| Hemoglobin |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| LDL Cholesterol |
0 |
0.07 |
| Salary and Compensation |
0 |
0.07 |
| Statins |
0 |
0.07 |